Eric Keller, J.D.
Chief Executive Officer, Founder & Chairman
Eric Keller is a proven business and legal executive with nearly 30 years of experience in life sciences-based companies. In addition to his role as Founder and CEO of Response Pharmaceutical, he is the Founder and CEO of Redux Therapeutics, a therapeutic asset acquisition and development company, as well as Response Pharmaceuticals sister company, Retension Pharmaceuticals.
Paul Sweetnam, Ph.D.
Chief Scientific Officer & Co-Founder
Paul has over 25 years of experience in senior scientific and management roles in pharmaceuticals and biotechnology. Notably, he led the discovery of RDX-002 at Surface Logix, Inc. and contributed to transitioning eight candidate molecules into clinical development at Bayer Healthcare, including Nexavar.
William Sasiela, Ph.D.
Chief Medical Officer
Bill has focused his career on developing therapeutics combating cardiometabolic diseases. During his 25 year tenure in the biopharmaceutical and biotech industry, Bill has played crucial roles in developing groundbreaking cardiovascular and metabolic drugs, including Lipitor, Juxtapid, Praluent, Evkeeza, and Nexletol. His expertise in development of cardiometabolic therapies is widely recognized in the industry.
Craig M. Audet, Ph.D.
Chief Regulatory Officer
Craig held leadership roles at Pfizer, Sanofi, Arena Pharmaceuticals, and Evofem Biosciences, and has 36+ years’ experience in pharmaceuticals and medical devices. Craig has extensive expertise in regulatory strategy across all stages of development and has been involved in development and commercialization of numerous therapeutics. He holds degrees from Boston College and Walden University.
Management
Ben de la Cretaz, MBA
Chief Financial Officer
Ben has nearly 20 years of experience in supporting startup operations. As a former founder and operator, he now leverages his expertise to assist founding teams and growth-stage companies with finance, fundraising, and operations as a CFO Partner at TechCXO. He holds an undergraduate degree from Pomona College and an MBA from Babson College, where he was a Fellow.
Sabine Bisson. Ph.D.
Senior Vice President, Operations
Sabine is an accomplished leader in the biotech industry with nearly 20 years of experience spearheading drug development efforts across the R&D lifecycle. She has played a key role in the development of many lifesaving therapeutics, including the CV metabolism drug PRALUENT®, and the Immuno-Oncology agent LIBTAYO®.. Trained in Germany, Canada, and the US, Sabine has focused her career on creating innovative therapies for patients with high unmet medical needs.
John W. Ferkany, Ph.D.
Senior Vice President, Development
John has been instrumental at Response since its beginning. He significantly aided the development and trials of RDX-002, drawing on extensive scientific and drug development expertise. He holds degrees from the University of Michigan, University of Texas, and Johns Hopkins.
Linda Zamarka M.S.
Head, Clinical Operations
Linda is a Drug Development Professional with over 30 years of experience, specializing in clinical operations, compliance and clinical trials across multiple therapeutic areas. She has extensive experience leading global programs and managing regulatory submissions and vendor relationships. Linda holds a B.S. in Biology and an M.S. in Clinical Research and Biostatistics.